Comparative Pharmacology
Head-to-head clinical analysis: ECOZA versus MENTAX TC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ECOZA versus MENTAX TC.
ECOZA vs MENTAX-TC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imidazole antifungal inhibiting ergosterol synthesis via CYP51, disrupting fungal cell membrane permeability.
MENTAX-TC (butenafine hydrochloride) is a benzylamine antifungal agent that inhibits the synthesis of ergosterol, a critical component of fungal cell membranes, by inhibiting the enzyme squalene epoxidase. This leads to accumulation of squalene and disruption of membrane integrity, resulting in fungal cell death.
For vulvovaginal candidiasis: One vaginal suppository (150 mg) inserted intravaginally at bedtime for 3 consecutive days. For cutaneous candidiasis: Apply cream (1%) to affected area twice daily for 2-4 weeks.
Apply a thin layer to affected area once daily for 2-4 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 24–30 hours, allowing for once-daily dosing.
Terminal elimination half-life is approximately 20 hours (range 16-24 hours), allowing once-daily dosing.
Primarily hepatic metabolism; <1% excreted renally as unchanged drug. Fecal excretion accounts for ~57% of metabolites.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine, ~60% in feces as metabolites, <1% in bile as unchanged drug.
Category C
Category C
Topical Antifungal
Topical Antifungal